These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3943010)

  • 41. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
    Weinfeld A; Swolin B; Westin J
    Eur J Haematol; 1994 Mar; 52(3):134-9. PubMed ID: 8168592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera.
    Oskay T; Kutluay L; Ozyilkan O
    Eur J Dermatol; 2002; 12(6):586-8. PubMed ID: 12459535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study.
    Büyükaşık Y; Ali R; Turgut M; Saydam G; Yavuz AS; Ünal A; Ar MC; Ayyıldız O; Altuntaş F; Okay M; Çiftçiler R; Meletli Ö; Soyer N; Mastanzade M; Güven Z; Soysal T; Karakuş A; Yiğenoğlu TN; Uçar B; Gökçen E; Tuğlular T
    Turk J Haematol; 2020 Aug; 37(3):177-185. PubMed ID: 32075363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular events and intensity of treatment in polycythemia vera.
    Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
    N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cutaneous effects after prolongaded use of hydroxyurea in Polycythemia Vera.
    França ER; Teixeira MA; Matias Kde F; Antunes DE; Braz Rde A; Silva CE
    An Bras Dermatol; 2011; 86(4):751-4. PubMed ID: 21987143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombotic complications of polycythemia vera.
    Varma S; Sharma A; Malhotra P; Kumari S; Jain S; Varma N
    Hematology; 2008 Dec; 13(6):319-23. PubMed ID: 19055858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with polycythemia vera after long-term hydroxyurea treatment.
    Su L; Zheng J; Xiu L; Li J; Ding M; He W
    Leuk Lymphoma; 2011 Nov; 52(11):2193-4. PubMed ID: 21718133
    [No Abstract]   [Full Text] [Related]  

  • 51. The optimal management of polycythaemia vera.
    McMullin MF; Bareford D; Craig J; Green AR; Harrison C; Oscier DG; Reilly JT;
    Br J Haematol; 2003 Feb; 120(3):543-4; author reply 544-5. PubMed ID: 12580978
    [No Abstract]   [Full Text] [Related]  

  • 52. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epstein-Barr virus-positive mucocutaneous ulcer in a patient with polycythemia vera treated with oral hydroxyurea.
    Hamada T; Kawata M; Maeda Y; Yoshino T; Miyake T; Morizane S; Hirai Y; Iwatsuki K
    J Dermatol; 2018 Apr; 45(4):e82-e83. PubMed ID: 29139148
    [No Abstract]   [Full Text] [Related]  

  • 54. Platelet transfusion for surgery in the presence of polycythemia vera.
    Terasako K; Sasai S
    Acta Anaesthesiol Scand; 1998 Feb; 42(2):270-1. PubMed ID: 9509216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
    Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
    Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hydroxyurea and sickle cell crisis.
    Silver RT
    N Engl J Med; 1995 Oct; 333(15):1008-9. PubMed ID: 7666903
    [No Abstract]   [Full Text] [Related]  

  • 57. Polycythemia vera with uncommon presentations.
    Dincer AP; Subramanian S; Goksel M
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):665-6; discussion 667. PubMed ID: 16258466
    [No Abstract]   [Full Text] [Related]  

  • 58. Polycythemia vera.
    Murphy S
    Dis Mon; 1992 Mar; 38(3):153-212. PubMed ID: 1587207
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hydroxyurea--is it a harmless drug in Vaquez disease?]].
    Rain JD
    Pathol Biol (Paris); 2001 Mar; 49(2):158-63. PubMed ID: 11317962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
    Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
    Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.